Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2019 08:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer

BERKELEY, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING)...
April 18, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors

BERKELEY, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING)...
April 17, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting

BERKELEY, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING)...
April 01, 2019 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference

BERKELEY, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled...
March 07, 2019 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at Two Upcoming Investor Conferences in March

BERKELEY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Aduro management is scheduled to present at the following investor conferences: 39th...
February 28, 2019 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019

BERKELEY, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that three abstracts will be presented at the American Association for Cancer Research (AACR)...
February 27, 2019 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results

BERKELEY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an...
February 21, 2019 08:15 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference

BERKELEY, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled...
February 21, 2019 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Announces Changes to its Board of Directors

BERKELEY, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the appointment of David H. Mack, Ph.D., President and CEO of PMV Pharmaceuticals, to its Board...
February 11, 2019 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma

BERKELEY, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel...